Nothing new here from Villeroy who also spoke yesterday here. Villeroy has been leaning on the dovish side for several months, but this comment sounds like he's fine with the current monetary policy and doesn't see the need of another cut anymore.
ADVERTISEMENT - CONTINUE READING BELOW
Search investingLive
ECB's Villeroy: Victory over inflation in France looks lasting
- Comments from the ECB policymaker, Francois Villeroy
ADVERTISEMENT - CONTINUE READING BELOW
- Tags
- ECB
Most Popular
- FT: Trump is pushing for 15 – 20% minimum tariff on all EU goods. EURUSD moves lower.
- ICYMI (Monday): Japan signals FX intervention readiness, vowing to shield US bond market
- ICYMI - Iran launches Bitcoin-backed ship insurance scheme for Strait of Hormuz transit
- Japan economy minister backs recovery but warns of Middle East conflict fallout risk
- RBA minutes: Eight of nine members backed May hike as inflation expectations risk grew
- Japan Q1 GDP beats forecasts at 2.1% but Iran war energy shock threatens momentum
- ICYMI - EU plans supply chain rules forcing firms to source key parts from three suppliers
ADVERTISEMENT - CONTINUE READING BELOW
Best in 2026
Sponsored
ADVERTISEMENT - CONTINUE READING BELOW
ADVERTISEMENT - CONTINUE READING BELOW
Telegram Community
Gain Access
Value stocks like EPC (8.8x P/E) & PSKY (13.2x P/E) risk being traps. GDRX (7.9x P/E) faces headwinds.
StockStory
1m ago
Asian shares mixed amid Iran war fears; Japan's economy grows, but Kospi sinks 4%. Oil prices gyrate.
Associated Press
4m ago
Industrials gain 24.5%, but NDSN, AEIS, MEI show weak growth & high P/E ratios.
StockStory
13m ago
SCI's weak FCF margin (14.4%) and low returns raise red flags. NFLX & AMGN show strong FCF margins (25.4%, 27.7%) & growth.
StockStory
26m ago
Japan's economy grew 2.1% annualized, boosted by consumer/govt spending despite oil price risks. Nikkei dips.
Associated Press
29m ago
POST's 5.8% ROIC & 13.2x P/E raise concerns. ADUS's $1.45B revenue & 13.4x P/E lag. GBCI's EPS fell 5.3%.
StockStory
38m ago
Regeneron shares tumble 10% as its melanoma drug fails late-stage trial, missing key goals.
Investor's Business Daily
41m ago
Telegram Community
Gain Access
Best in 2026
Sponsored
Must Read
!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|} !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}